The FDA is holding a 2-day stem cell meeting starting tomorrow and it promises to be a really big deal. What’s the scoop on this meeting and the attendees? Who is likely to say what? If the deregulatory proponents get their way, could we have stem cell clinics like Starbucks popping up in even more neighborhoods? I have […]
Guide to September 12-13 FDA Stem Cell Meeting Read More »
The stem cell clinic trial being run by Asterias Biotherapeutics for spinal cord injury (SCI) reported (via CIRM) some preliminary very good news as it is so far seems safe and will be expanded to involve more patients. In the next phase, reportedly “Asterias is now looking to enroll 5-8 patients for this 20 million
Stem cell good news as Asterias SCI trial to expand with strong safety data Read More »
That much-anticipated public FDA stem cell meeting that was postponed from April will now take place in September and will have a much larger array of diverse speakers. Many more voices at an FDA stem cell meeting are collectively a good thing, but delay is not. The large and growing U.S. stem cell clinic industry makes
September FDA stem cell meeting looks to be big debate Read More »
Need a fix of some stem cell good news? I do. It has been a bumpy 2016 so far for the stem cell field and many challenges have popped up. So today at lunch and needing at least a short break from grant writing, I went looking for stem cell good news including interesting studies, promising
List of 11 stem cell good news or interesting stories Read More »
ISSCR 2016’s first plenary session is focused on stem cells & cancer. I was really excited about this one even before the meeting as this topic is a major focus of my own lab. Here’s the lineup for this plenary with great expertise in stem cells & cancer from across the globe: President’s Address: Sean Morrison, Children’s
Austin Smith talk at ISSCR 2016: a ground state inhibitor pathway Read More »
A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for
End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »
The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers
UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease Read More »
Some stuff on my mind for our TGIF Science this week. Research Funding Ups: NIH. Is it my imagination or is NIH funding slightly improving? This is the overall vibe I’m hearing from the trenches. Research Funding Ups and Downs: CIRM. CIRM funded some basic research to the tune of a total of $4 million,
TGIF Science: funding, CRISPR v. NgAgo, secrets, Zika, & more Read More »
What are the top 10 stem cell websites? Where do you go to find the latest information and opinion on the stem cell and regenerative medicine fields? Today, that information flows almost from minute to minute via websites and from social media. This is a transformational difference from past decades when it would take months.
10 go-to stem cell & regenerative medicine websites of 2016 Read More »
I talked last year about human genetic modification by CRISPR with George Church a year ago. Now we’ve followed up with a long chat on this topic going into much more detail and with questions on recent developments. Each question is listed numerically and then there is a back and forth on that question with George
George Church chat: CRISPR people, Zika, weapons Read More »